Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Colorectal cancer
MSI-H immunotherapy, BRAF V600E, HER2 and KRAS G12C combinations.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:25 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
600
the 600 most recently updated are shown
For relapsed or refractory disease
6%
34 trial titles name relapsed, refractory or recurrent disease
Led by industry
49%
295 trials with a company as lead sponsor
81 of the 600 colorectal cancer trials are Phase 3; 34 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of colorectal cancer (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 118 of 600 trials name no segment and are listed as Untagged.
Segment:All1L1L · Advanced or metastatic1L · Locally advanced2L+2L+ · Advanced or metastatic2L+ · Locally advanced2L+ · Relapsed or refractoryAdjuvantAdvanced or metastaticBRAF V600EBRAF V600E · Advanced or metastaticBRAF V600E · Neoadjuvant or perioperativeBRAF V600E · Relapsed or refractorydMMRdMMR · Advanced or metastaticdMMR · Neoadjuvant or perioperativeHER2HER2 · 1L · Advanced or metastaticHER2 · 2L+HER2 · Advanced or metastaticHER2 · Locally advancedKRASKRAS · 1L · Advanced or metastaticKRAS · Adjuvant
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Bevacizumab Hoffmann-La Roche | Advanced or metastatic | Antibody | Ph3 | NCT04929223, NCT07915921, NCT07271355, NCT05462613 +34 |
| Oxaliplatin Genfleet Therapeutics (Shanghai) Inc. | Advanced or metastatic | Other or not recognised | Ph3 | NCT07915921, NCT05379595, NCT01225744, NCT06820463 +17 |
| Cetuximab Hoffmann-La Roche | Advanced or metastatic | Antibody | Ph3 | NCT04929223, NCT07915921, NCT07397338, NCT07702032 +16 |
| Irinotecan Genfleet Therapeutics (Shanghai) Inc. | Advanced or metastatic | Other or not recognised | Ph3 | NCT07915921, NCT05379595, NCT01220063, NCT01225744 +14 |
| Fluorouracil Genfleet Therapeutics (Shanghai) Inc. | Advanced or metastatic | Other or not recognised | Ph3 | NCT07915921, NCT07271355, NCT05379595, NCT06820463 +13 |
| Leucovorin Genfleet Therapeutics (Shanghai) Inc. | Advanced or metastatic | Other or not recognised | Ph3 | NCT07915921, NCT05379595, NCT06820463, NCT02997228 +12 |
| Bevacizumab Merck Sharp & Dohme LLC | Untagged | Antibody | Ph3 | NCT06997497, NCT07900165, NCT06547385, NCT05482516 +7 |
| Oxaliplatin Institut du Cancer de Montpellier - Val d'Aurelle | Locally advanced | Other or not recognised | Ph3 | NCT03255434, NCT04703101, NCT02912559, NCT07847229 +7 |
| Capecitabine Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Neoadjuvant or perioperative | Other or not recognised | Ph3 | NCT07580339, NCT02505750, NCT06850090, NCT04495088 +5 |
| Nivolumab M.D. Anderson Cancer Center | Relapsed or refractory | Antibody | Ph3 | NCT04017650, NCT07011550, NCT02465060, NCT04444921 +4 |
| Capecitabine Jonsson Comprehensive Cancer Center | Locally advanced | Other or not recognised | Ph2/Ph3 | NCT04703101, NCT07847229, NCT04929028, NCT05610163 +3 |
| Cetuximab Kumquat Biosciences Inc. | KRAS G12C · Advanced or metastatic | Antibody | Ph3 | NCT06720987, NCT05358249, NCT07814417, NCT04793958 +3 |
| Fluorouracil Jonsson Comprehensive Cancer Center | Locally advanced | Other or not recognised | Ph3 | NCT04703101, NCT02912559, NCT04929028, NCT06696768 +3 |
| FOLFIRI Hoffmann-La Roche | Advanced or metastatic | Other or not recognised | Ph3 | NCT04929223, NCT06663319, NCT07702032, NCT07649655 +3 |
| Bevacizumab Pfizer | 1L · Advanced or metastatic | Antibody | Ph3 | NCT04607421, NCT07500298, NCT07284849, NCT07221357 +2 |
| Capecitabine National Cancer Institute (NCI) | Advanced or metastatic | Other or not recognised | Ph3 | NCT05803382, NCT05863195, NCT05489211, NCT07805551 +2 |
| Cetuximab M.D. Anderson Cancer Center | Relapsed or refractory | Antibody | Ph3 | NCT04017650, NCT06102902, NCT07775287, NCT04616183 +2 |
| Oxaliplatin National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph3 | NCT04847063, NCT06997497, NCT06547385, NCT06788171 +2 |
| Regorafenib Centre Hospitalier Universitaire de Besancon | Advanced or metastatic | Small molecule | Ph2/Ph3 | NCT06425133, NCT05462613, NCT05985109, NCT06887218 +2 |
| Bevacizumab Genmab | Relapsed or refractory | Antibody | Ph3 | NCT07775287, NCT07011550, NCT07525206, NCT01205022 +1 |
| Cetuximab Merck Sharp & Dohme LLC | Untagged | Antibody | Ph3 | NCT06997497, NCT06358430, NCT07411599, NCT05722327 +1 |
| Floxuridine National Cancer Institute (NCI) | Advanced or metastatic | Other or not recognised | Ph3 | NCT05286814, NCT07842965, NCT05863195, NCT03366155 +1 |
| Fluorouracil Merck Sharp & Dohme LLC | Untagged | Other or not recognised | Ph3 | NCT06428409, NCT06547385, NCT04166318, NCT07844187 +1 |
| Leucovorin Calcium National Cancer Institute (NCI) | Locally advanced | Other or not recognised | Ph3 | NCT02912559, NCT05610163, NCT06696768, NCT07363408 +1 |
| Nivolumab National Cancer Institute (NCI) | Locally advanced | Antibody | Ph3 | NCT03233711, NCT04751370, NCT05919264, NCT04929028 +1 |
| TAS-102 Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced or metastatic | Other or not recognised | Ph3 | NCT07649655, NCT06039202, NCT05328908, NCT04999761 +1 |
| Bevacizumab National Cancer Institute (NCI) | Locally advanced | Antibody | Ph3 | NCT00569127, NCT05919264, NCT06696768, NCT03715933 |
| Cetuximab Verastem, Inc. | KRAS | Antibody | Ph3 | NCT07020221, NCT06750094, NCT07659795, NCT06586515 |
| Nivolumab Exelixis | Untagged | Antibody | Ph3 | NCT07620574, NCT06638931, NCT06047379, NCT04912765 |
| 5-FU Toray Industries, Inc | Advanced or metastatic | Other or not recognised | Ph3 | NCT03872947, NCT07474727, NCT04776655 |
| Atezolizumab Hoffmann-La Roche | Advanced or metastatic | Antibody | Ph3 | NCT04929223, NCT02997228, NCT05243862 |
| Atezolizumab Genentech, Inc. | Locally advanced | Antibody | Ph3 | NCT05581004, NCT02912559, NCT03170960 |
| CAPOX Ruijin Hospital | Neoadjuvant or perioperative | Other or not recognised | Ph3 | NCT07888309, NCT07877597, NCT07819604 |
| Cetuximab Pfizer | 1L · Advanced or metastatic | Antibody | Ph3 | NCT04607421, NCT07621497, NCT05217446 |
| Irinotecan Alliance for Clinical Trials in Oncology | Locally advanced | Other or not recognised | Ph2/Ph3 | NCT05610163, NCT03715933, NCT07363408 |
| Leucovorin Calcium City of Hope Medical Center | Advanced or metastatic | Other or not recognised | Ph3 | NCT07271355, NCT04094688, NCT05627635 |
| Oxaliplatin Genmab | Relapsed or refractory | Other or not recognised | Ph3 | NCT07775287, NCT02041481, NCT03203525 |
| Oxaliplatin Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Neoadjuvant or perioperative | Other or not recognised | Ph3 | NCT07580339, NCT07801352, NCT01918527 |
| Panitumumab AbbVie | Advanced or metastatic | Antibody | Ph3 | NCT06820463, NCT05863195, NCT03366155 |
| 5-fluorouracil Janssen Research & Development, LLC | KRAS | Other or not recognised | Ph3 | NCT06750094, NCT06586515 |
| 5-fluorouracil Alliance for Clinical Trials in Oncology | Locally advanced | Other or not recognised | Ph2/Ph3 | NCT05610163, NCT02008656 |
| 5-Fluorouracil National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph3 | NCT04847063, NCT06997497 |
| 5FU, Prof. Dr. med. Claus Rödel | Locally advanced | Other or not recognised | Ph3 | NCT04246684, NCT04246684 |
| Atezolizumab Exelixis | Untagged | Antibody | Ph3 | NCT07620574, NCT05482516 |
| Bevacizumab Oncolytics Biotech | 2L+ · Advanced or metastatic | Antibody | Ph3 | NCT07446322, NCT07549412 |
| Capecitabine, Prof. Dr. med. Claus Rödel | Locally advanced | Other or not recognised | Ph3 | NCT04246684, NCT04246684 |
| Encorafenib Pfizer | 1L · Advanced or metastatic | Small molecule | Ph3 | NCT04607421, NCT05217446 |
| FOLFOX Incyte Corporation | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT07284849, NCT07221357 |
| Irinotecan Genmab | Relapsed or refractory | Other or not recognised | Ph3 | NCT07775287, NCT01394939 |
| Irinotecan Janssen Research & Development, LLC | KRAS | Other or not recognised | Ph3 | NCT06750094, NCT06586515 |
| Irinotecan Bristol-Myers Squibb | MSI-H · Advanced or metastatic | Other or not recognised | Ph3 | NCT04008030, NCT06974110 |
| Irinotecan Hydrochloride City of Hope Medical Center | Advanced or metastatic | Other or not recognised | Ph3 | NCT07271355, NCT04094688 |
| Leucovorin Genmab | Relapsed or refractory | Other or not recognised | Ph3 | NCT07775287, NCT03203525 |
| Leucovorin Bristol-Myers Squibb | MSI-H · Advanced or metastatic | Other or not recognised | Ph3 | NCT04008030, NCT05714553 |
| mFOLFOX Ralf Hofheinz | Neoadjuvant or perioperative | Other or not recognised | Ph3 | NCT04495088, NCT04495088 |
| mFOLFOX6 Genmab | Advanced or metastatic | Other or not recognised | Ph3 | NCT07702032, NCT07649655 |
| Mitomycin City of Hope Medical Center | Advanced or metastatic | Other or not recognised | Ph3 | NCT07271355, NCT04329494 |
| MRTX849 Mirati Therapeutics Inc. | KRAS G12C · Advanced or metastatic | Other or not recognised | Ph3 | NCT04793958, NCT03785249 |
| Oxaliplatin Pfizer | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT04607421, NCT07621497 |
| Oxaliplatin, Prof. Dr. med. Claus Rödel | Locally advanced | Other or not recognised | Ph3 | NCT04246684, NCT04246684 |
Showing the 60 most advanced of 1039 programs.
Assets over time
600 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Bevacizumab | Oncolytics Biotech | |
| Capecitabine | Jonsson Comprehensive Cancer Center | |
| Nivolumab | National Cancer Institute (NCI) | |
| Regorafenib | Centre Hospitalier Universitaire de Besancon | |
| Retifanlimab | Memorial Sloan Kettering Cancer Center | |
| Atezolizumab | National Cancer Institute (NCI) | |
| Telisotuzumab Adizutecan | AbbVie | |
| Ipilimumab | National Cancer Institute (NCI) | |
| MRTX849 | Mirati Therapeutics Inc. | |
| Encorafenib | Pfizer | |
| Amivantamab | Janssen Research & Development, LLC | |
| Petosemtamab | Genmab | |
| INCA33890 | Incyte Corporation | |
| Cabozantinib | Exelixis | |
| Serplulimab | Fudan University | |
| TAS-102 | Shandong Cancer Hospital and Institute | |
| Zanzalintinib | Exelixis | |
| Sotorasib | Amgen | |
| tucatinib | Seagen, a wholly owned subsidiary of Pfizer | |
| Patients receive standard second-line therapy combined with oral chidamide | Sir Run Run Shaw Hospital | |
| Oral chidamide treatment | Sir Run Run Shaw Hospital | |
| Drug: Ivonescimab Injection | Summit Therapeutics | |
| Precemtabart tocentecan | EMD Serono Research & Development Institute, Inc. | |
| mFOLFOX6 3-6 month | NRG Oncology | |
| Calderasib | Merck Sharp & Dohme LLC | |
| GFH375 + Cetuximab | Genfleet Therapeutics (Shanghai) Inc. | |
| Rilogrotug | AVEO Pharmaceuticals, Inc. | |
| Pumitamig | Bristol-Myers Squibb | |
| Romiplostim | Amgen | |
| Eflornithine plus sulindac | SWOG Cancer Research Network |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07927049 Evaluating the Efficacy of Chidamide in the Treatment of Initial Unresectable Metastatic Colorectal Cancer With High Expression of SULF1 Single-country: China (1 site) Decision brief → | Ph2/Ph3 | Sir Run Run Shaw Hospital | enrolling by invitation | 2026-11-09 | 2028-06-01 |
| NCT07927075 Evaluating the Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With High SULF1 Expression Single-country: China (1 site) Decision brief → | Ph2/Ph3 | Sir Run Run Shaw Hospital | enrolling by invitation | 2026-11-09 | 2028-06-01 |
| NCT07913360 GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer No sites listed Decision brief → | Ph3 | Genfleet Therapeutics (Shanghai) Inc. | not yet recruiting | 2026-11-03 | 2028-11 |
| mRCATS · NCT07900061 Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer No sites listed Decision brief → | Ph3 | Sir Run Run Shaw Hospital | not yet recruiting | 2026-10-28 | 2031-12 |
| REACH · NCT07888075 Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC No sites listed Decision brief → | Ph2/Ph3 | AVEO Pharmaceuticals, Inc. | not yet recruiting | 2026-10-22 | 2030-03 |
| NCT07885384 Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer No sites listed Decision brief → | Ph3 | West China Hospital | not yet recruiting | 2026-10-21 | 2029-04-28 |
| TORCH-C2 · NCT07877597 Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS Single-country: China (1 site) Decision brief → | Ph3 | Fudan University | not yet recruiting | 2026-10-16 | 2029-12-31 |
| TORCH-PM02 · NCT07815834 FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02) Single-country: China (1 site) Decision brief → | Ph3 | Fudan University | recruiting | 2026-09-11 | 2030-08-01 |
| NCT07775287 Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) 2 countries, 80% of sites in the US Decision brief → | Ph3 | Genmab | recruiting | 2026-08-20 | 2029-03-30 |
| STELLAR-316 · NCT07750158 Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Single-country: United States (13 sites) Decision brief → | Ph3 | Exelixis | recruiting | 2026-08-06 | 2030-04-05 |
| DuraSTAR · NCT07740720 A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer No sites listed Decision brief → | Ph3 | GlaxoSmithKline | not yet recruiting | 2026-08-03 | 2029-12-12 |
| NCT07736495 Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis Single-country: Egypt (1 site) Decision brief → | Ph2/Ph3 | Ain Shams University | recruiting | 2026-07-30 | 2026-12-27 |
| NCT07730489 A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan Single-country: China (2 sites) Decision brief → | Ph3 | Sichuan Baili Pharmaceutical Co., Ltd. | not yet recruiting | 2026-07-28 | 2027-12 |
| FIRBIT · NCT07729605 FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC Single-country: China (1 site) Decision brief → | Ph3 | Sun Yat-sen University | not yet recruiting | 2026-07-27 | 2028-12-30 |
| NCT07722494 IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer Single-country: China (2 sites) Decision brief → | Ph3 | Innovent Biologics (Suzhou) Co. Ltd. | recruiting | 2026-07-23 | 2028-10-31 |
| NCT07702032 Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) 3 countries, 75% of sites in the US Decision brief → | Ph3 | Genmab | recruiting | 2026-07-14 | 2029-07 |
| NCT07676162 A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | recruiting | 2026-06-30 | 2029-09 |
| NuvastaticTM · NCT07669519 Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy Single-country: India (6 sites) Decision brief → | Ph3 | Natureceuticals Sdn Bhd | recruiting | 2026-06-25 | 2027-03-31 |
| NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Single-country: United States (4 sites) Decision brief → | Ph3 | Exelixis | enrolling by invitation | 2026-06-02 | 2030-05-31 |
| NCT07595276 Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. Single-country: China (1 site) Decision brief → | Ph3 | Taizhou Mabtech Pharmaceutical Co.,Ltd | recruiting | 2026-05-19 | 2029-10-01 |
| NCT07549412 A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) 19 countries, 19% of sites in the US Decision brief → | Ph3 | EMD Serono Research & Development Institute, Inc. | recruiting | 2026-04-24 | 2029-10-16 |
| AndroMETa-CRC · NCT07525206 A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer 10 countries, 20% of sites in the US Decision brief → | Ph3 | AbbVie | recruiting | 2026-04-13 | 2029-05 |
| SUIVICOLO · NCT07520578 EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO) Single-country: France (1 site) Decision brief → | Ph3 | University Hospital, Caen | recruiting | 2026-04-09 | 2027-03-24 |
| DETERMINE · NCT07440290 DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Single-country: United Kingdom (27 sites) Decision brief → | Ph2/Ph3 | Cancer Research UK | recruiting | 2026-02-27 | 2029-10 |
| CIRCULATEIII · NCT07340567 Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test 2 countries, 0% of sites in the US Decision brief → | Ph3 | UNICANCER | active not recruiting | 2026-01-14 | 2032-11-01 |
| NCT07284849 A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer 22 countries, 26% of sites in the US Decision brief → | Ph3 | Incyte Corporation | recruiting | 2025-12-16 | 2028-12-29 |
| NCT07271355 Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Single-country: United States (5 sites) Decision brief → | Ph3 | City of Hope Medical Center | recruiting | 2025-12-09 | 2031-02-28 |
| HARMONi-GI3 · NCT07228832 Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer 15 countries, 46% of sites in the US Decision brief → | Ph3 | Summit Therapeutics | recruiting | 2025-11-14 | 2028-05-31 |
| NCT07222800 Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer 17 countries, 68% of sites in the US Decision brief → | Ph3 | Pfizer | recruiting | 2025-10-30 | 2030-02-23 |
| NCT07221357 A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer 25 countries, 16% of sites in the US Decision brief → | Ph2/Ph3 | Bristol-Myers Squibb | recruiting | 2025-10-27 | 2030-02-02 |
| REACT · NCT07188025 ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer Single-country: Netherlands (25 sites) Decision brief → | Ph3 | Erasmus Medical Center | recruiting | 2025-09-23 | 2030-10 |
| NCT07132463 Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study Single-country: China (1 site) Decision brief → | Ph3 | Fudan University | recruiting | 2025-08-20 | 2027-12 |
| NCT07018869 Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors 3 countries, 98% of sites in the US Decision brief → | Ph3 | SWOG Cancer Research Network | recruiting | 2025-06-13 | 2031-10-28 |
| FIRE-11 · NCT07004413 Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients Single-country: Germany (1 site) Decision brief → | Ph3 | Charite University, Berlin, Germany | not yet recruiting | 2025-06-04 | 2028-10-01 |
| NCT06997497 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) 29 countries, 20% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2025-05-30 | 2029-03-28 |
| NCT06958432 Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) Single-country: China (1 site) Decision brief → | Ph2/Ph3 | Sixth Affiliated Hospital, Sun Yat-sen University | recruiting | 2025-05-06 | 2030-12-31 |
| NCT06862115 The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery Single-country: Egypt (1 site) Decision brief → | Ph3 | Kasr El Aini Hospital | completed | 2025-03-06 | 2026-08-10 |
| NCT06850090 Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial Single-country: China (1 site) Decision brief → | Ph3 | Shandong Cancer Hospital and Institute | recruiting | 2025-02-27 | 2027-06 |
| OrigAMI-3 · NCT06750094 A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy 26 countries, 28% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | recruiting | 2024-12-27 | 2027-12-15 |
| OrigAMI-2 · NCT06662786 A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer 22 countries, 34% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | recruiting | 2024-10-29 | 2028-12-15 |
| IRIMAD · NCT06501482 Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI Single-country: France (1 site) Decision brief → | Ph3 | Assistance Publique - Hôpitaux de Paris | recruiting | 2024-07-15 | 2028-06-27 |
| NOTABLE-308 · NCT06343116 Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer No sites listed Decision brief → | Ph3 | Biotech Pharmaceutical Co., Ltd. | withdrawn | 2024-04-02 | 2027-04 |
| CodeBreaK 301 · NCT06252649 Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation 35 countries, 9% of sites in the US Decision brief → | Ph3 | Amgen | recruiting | 2024-02-12 | 2028-09-25 |
| NCT06246344 Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer Single-country: China (1 site) Decision brief → | Ph3 | Shandong Cancer Hospital and Institute | active not recruiting | 2024-02-07 | 2025-12-01 |
| SPACE · NCT06119867 CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE) Single-country: Russia (1 site) Decision brief → | Ph3 | Russian Society of Colorectal Surgeons | recruiting | 2023-11-07 | 2027-04-12 |
| NCT06008119 Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph3 | Shanghai Kechow Pharma, Inc. | recruiting | 2023-08-23 | 2026-12-24 |
| NCT05863195 Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Single-country: United States (62 sites) Decision brief → | Ph3 | ECOG-ACRIN Cancer Research Group | recruiting | 2023-05-17 | 2029-06-30 |
| NCT05752136 Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma Single-country: China (1 site) Decision brief → | Ph3 | Sir Run Run Shaw Hospital | recruiting | 2023-03-02 | 2026-11-01 |
| JANUS · NCT05610163 Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response 2 countries, 99% of sites in the US Decision brief → | Ph2/Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2022-11-09 | 2030-07-01 |
| CLAUDIA · NCT05534087 Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) Single-country: South Korea (13 sites) Decision brief → | Ph3 | Seoul National University Hospital | recruiting | 2022-09-09 | 2028-09-30 |
| MRD-GI · NCT05482516 Evaluating Novel Therapies in ctDNA Positive GI Cancers Single-country: United States (1 site) Decision brief → | Ph3 | Georgetown University | active not recruiting | 2022-08-01 | 2026-08-20 |
| REPROGRAM-02 · NCT05462613 Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer Single-country: France (14 sites) Decision brief → | Ph2/Ph3 | Centre Hospitalier Universitaire de Besancon | active not recruiting | 2022-07-18 | 2029-11 |
| RELATIVITY-123 · NCT05328908 A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer 22 countries, 14% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | terminated | 2022-04-14 | 2025-07-14 |
| MOUNTAINEER-03 · NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer 25 countries, 36% of sites in the US Decision brief → | Ph3 | Seagen, a wholly owned subsidiary of Pfizer | recruiting | 2022-02-24 | 2027-12-31 |
| CodeBreak300 · NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation 12 countries, 19% of sites in the US Decision brief → | Ph3 | Amgen | completed | 2022-01-20 | 2025-07-16 |
| CIRCULATE-US · NCT05174169 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease 3 countries, 96% of sites in the US Decision brief → | Ph2/Ph3 | NRG Oncology | recruiting | 2021-12-30 | 2029-03-10 |
| NCT04793958 Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) 32 countries, 44% of sites in the US Decision brief → | Ph3 | Mirati Therapeutics Inc. | active not recruiting | 2021-03-11 | 2026-01-16 |
| LIBImAb · NCT04776655 Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB Single-country: Italy (4 sites) Decision brief → | Ph3 | Azienda USL Reggio Emilia - IRCCS | active not recruiting | 2021-03-02 | 2025-05-04 |
| GRECCAR14 · NCT04749108 Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma Single-country: France (30 sites) Decision brief → | Ph2/Ph3 | Institut du Cancer de Montpellier - Val d'Aurelle | recruiting | 2021-02-11 | 2029-09 |
| NCT04607421 A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer 29 countries, 23% of sites in the US Decision brief → | Ph3 | Pfizer | active not recruiting | 2020-10-29 | 2025-03-01 |
| NCT04495088 Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Single-country: Germany (1 site) Decision brief → | Ph3 | Ralf Hofheinz | terminated | 2020-07-31 | 2026-07-31 |
| NCT04472429 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). 13 countries, 17% of sites in the US Decision brief → | Ph3 | Incyte Corporation | completed | 2020-07-15 | 2024-04-15 |
| NCT04444921 EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients Single-country: United States (579 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2020-06-24 | 2027-03-31 |
| NCT04246684 Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients Single-country: Germany (75 sites) Decision brief → | Ph3 | Prof. Dr. med. Claus Rödel | active not recruiting | 2020-01-29 | 2026-09-15 |
| SOLARIS · NCT04094688 Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer 2 countries, 100% of sites in the US Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2019-09-19 | 2024-07-15 |
| CheckMate 8HW · NCT04008030 A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) 24 countries, 6% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | active not recruiting | 2019-07-05 | 2024-08-28 |
| NCT03803553 Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer Single-country: United States (3 sites) Decision brief → | Ph3 | Massachusetts General Hospital | active not recruiting | 2019-01-14 | 2026-12 |
| RECITE · NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer 20 countries, 19% of sites in the US Decision brief → | Ph3 | Amgen | completed | 2017-12-05 | 2024-01-25 |
| ASAC · NCT03326791 Aspirin in Colorectal Cancer Liver Metastases 3 countries, 0% of sites in the US Decision brief → | Ph2/Ph3 | Oslo University Hospital | completed | 2017-10-31 | 2022-02-01 |
| NCT03233711 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer 2 countries, 99% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2017-07-31 | 2027-12-31 |
| NCT02997228 Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study Single-country: United States (445 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2016-12-20 | 2027-06-01 |
| GASVERT · NCT02997553 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Single-country: France (1 site) Decision brief → | Ph3 | Institut de Cancérologie de Lorraine | completed | 2016-12-20 | 2022-09-19 |
| NCT02912559 Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair 3 countries, 98% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2016-09-23 | 2025-02-04 |
| OPERA · NCT02505750 Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma 3 countries, 0% of sites in the US Decision brief → | Ph3 | Centre Antoine Lacassagne | active not recruiting | 2015-07-22 | 2023-06-07 |
| CAPS5 · NCT02000089 The Cancer of the Pancreas Screening-5 CAPS5)Study Single-country: United States (9 sites) Decision brief → | Ph3 | Johns Hopkins University | recruiting | 2013-12-03 | 2028-12 |
| NCT01918527 Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer 3 countries, 0% of sites in the US Decision brief → | Ph3 | Vejle Hospital | completed | 2013-08-07 | 2023-06 |
| PACES · NCT01349881 S0820, Adenoma and Second Primary Prevention Trial Single-country: United States (989 sites) Decision brief → | Ph3 | SWOG Cancer Research Network | active not recruiting | 2011-05-09 | 2027-09-15 |
| COLOCROSS · NCT00905047 Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer Single-country: France (13 sites) Decision brief → | Ph3 | Centre Oscar Lambret | completed | 2009-05-20 | 2010-06 |
| NCT00569127 Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Single-country: United States (493 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2007-12-06 | 2015-01-01 |
| NCT00265850 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer 2 countries, 97% of sites in the US Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | completed | 2005-12-15 | 2015-02 |
| NCT00217737 Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer 5 countries, 98% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | completed | 2005-09-22 | 2024-02-22 |
| NCT07927998 A Study of Retifanlimab After Chemoradiation in People With Anal Cancer Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2026-11-10 | 2029-11-04 |
| NCT07926477 Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation No sites listed Decision brief → | Ph2 | Second Affiliated Hospital, Zhejiang University, School of Medicine | not yet recruiting | 2026-11-09 | 2029-12-01 |
| A Phase Ib/II · NCT07915921 A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer No sites listed Decision brief → | Ph1/Ph2 | Genfleet Therapeutics (Shanghai) Inc. | not yet recruiting | 2026-11-04 | 2028-04-30 |
| LEGEND · NCT07917104 Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After Resection Single-country: China (1 site) Decision brief → | Ph2 | Fudan University | recruiting | 2026-11-04 | 2029-11 |
| ACE-Dose-CRC · NCT07913906 Alberta Cancer Exercise Dose in Colorectal Cancer Single-country: Canada (1 site) Decision brief → | Ph2 | University of Calgary | not yet recruiting | 2026-11-03 | 2028-01 |
| NCT07912593 Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Ensem Therapeutics | recruiting | 2026-11-03 | 2028-10-30 |
| PRIM-CRC3 · NCT07904130 Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer No sites listed Decision brief → | Ph2 | West China Hospital | not yet recruiting | 2026-10-29 | 2028-10-01 |
| NCT07900165 Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer No sites listed Decision brief → | Ph1/Ph2 | CytomX Therapeutics | not yet recruiting | 2026-10-28 | 2029-02 |
| NCT07897227 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. No sites listed Decision brief → | Ph1/Ph2 | CSPC Megalith Biopharmaceutical Co.,Ltd. | not yet recruiting | 2026-10-27 | 2029-05-01 |
| NCT07896681 Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study Single-country: China (1 site) Decision brief → | Ph2 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | recruiting | 2026-10-27 | 2028-07-01 |
| NCT07896096 Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment Single-country: China (1 site) Decision brief → | Ph2 | Renmin Hospital of Wuhan University | recruiting | 2026-10-26 | 2027-12-30 |
| NCT07895355 Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph2 | RemeGen Co., Ltd. | not yet recruiting | 2026-10-26 | 2028-07 |
| TRIP-FAST · NCT07888309 SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer Single-country: China (1 site) Decision brief → | Ph2 | Ruijin Hospital | recruiting | 2026-10-22 | 2027-09-11 |
| NCT07884188 Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph2 | Fudan University | recruiting | 2026-10-20 | 2028-10-15 |
| ILDR-ICI-LM · NCT07875465 Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases Single-country: China (1 site) Decision brief → | Ph2 | Bing Xia | not yet recruiting | 2026-10-15 | 2029-04 |
| NCT07873450 SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET 2 countries, 50% of sites in the US Decision brief → | Ph1/Ph2 | Full-Life Technologies UK Limited | recruiting | 2026-10-14 | 2030-06-30 |
| NCT07863869 The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases No sites listed Decision brief → | Ph1/Ph2 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | not yet recruiting | 2026-10-07 | 2029-05-27 |
| NCT07863024 Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors No sites listed Decision brief → | Ph1/Ph2 | Regeneron Pharmaceuticals | not yet recruiting | 2026-10-07 | 2031-03-10 |
| RANDY 1A · NCT07856914 Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal Cancer No sites listed Decision brief → | Ph2 | Patrick Wagner, MD, FACS | not yet recruiting | 2026-10-05 | 2030-09 |
| NCT07847229 A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer Single-country: China (1 site) Decision brief → | Ph2 | Tao Zhang | not yet recruiting | 2026-09-29 | 2027-10-31 |
| NCT07844187 TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread Single-country: China (16 sites) Decision brief → | Ph1/Ph2 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | not yet recruiting | 2026-09-28 | 2027-08-31 |
| NCT07841236 ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer Single-country: China (1 site) Decision brief → | Ph2 | Fudan University | recruiting | 2026-09-25 | 2027-12-31 |
| TRIUNITE-08 · NCT07840677 Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer Single-country: China (1 site) Decision brief → | Ph2 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | recruiting | 2026-09-25 | 2029-09-20 |
| PKUCH-R10 · NCT07833319 Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer Single-country: China (1 site) Decision brief → | Ph2 | Peking University Cancer Hospital & Institute | recruiting | 2026-09-22 | 2027-07-01 |
| NEXERA-204 · NCT07823322 A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy No sites listed Decision brief → | Ph2 | Incyte Corporation | not yet recruiting | 2026-09-16 | 2029-05-14 |
| NCT07821333 Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III Single-country: Spain (7 sites) Decision brief → | Ph2 | Fundación para la Investigación del Hospital Clínico de Valencia | active not recruiting | 2026-09-15 | 2027-01-01 |
| NCT07819604 Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer No sites listed Decision brief → | Ph2 | Xijing Hospital | not yet recruiting | 2026-09-15 | 2027-09-01 |
| FOBEAR-ii · NCT07817888 mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer No sites listed Decision brief → | Ph2 | Sixth Affiliated Hospital, Sun Yat-sen University | not yet recruiting | 2026-09-14 | 2028-09-30 |
| NCT07814417 A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation 3 countries, 50% of sites in the US Decision brief → | Ph2 | Eli Lilly and Company | not yet recruiting | 2026-09-11 | 2028-11 |
| NCT07815288 Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases Single-country: China (1 site) Decision brief → | Ph2 | Peking University Cancer Hospital & Institute | not yet recruiting | 2026-09-11 | 2029-12-30 |
| NCT07811193 A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum 22 countries, 3% of sites in the US Decision brief → | Ph2 | Vividion Therapeutics, Inc. | recruiting | 2026-09-09 | 2028-06-30 |
| NCT07809893 Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients Single-country: China (1 site) Decision brief → | Ph2 | Sun Yat-sen University | recruiting | 2026-09-09 | 2027-12-31 |
| SPARE · NCT07810114 Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer Single-country: China (1 site) Decision brief → | Ph2 | Fudan University | not yet recruiting | 2026-09-09 | 2027-12-01 |
| NCT07808151 Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer 6 countries, 37% of sites in the US Decision brief → | Ph2 | Solstice Oncology, Inc. | recruiting | 2026-09-08 | 2029-09-30 |
| NCT07807800 A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) No sites listed Decision brief → | Ph1/Ph2 | D. E. Shaw Research, LLC | not yet recruiting | 2026-09-08 | 2028-07-02 |
| NCT07805551 A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | recruiting | 2026-09-04 | 2030-08 |
| NCT07801352 CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph2 | Shanghai Changzheng Hospital | active not recruiting | 2026-09-03 | 2025-07-28 |
| HORIZON-CRC221 · NCT07796763 A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2 Single-country: United States (1 site) Decision brief → | Ph2 | Jiangsu HengRui Medicine Co., Ltd. | not yet recruiting | 2026-09-01 | 2028-05-01 |
| NCT07797244 A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM) Single-country: China (1 site) Decision brief → | Ph2 | Dai, Guanghai | not yet recruiting | 2026-09-01 | 2029-04 |
| NCT07795749 Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) Single-country: United States (1 site) Decision brief → | Ph2 | University of California, Irvine | recruiting | 2026-08-31 | 2029-08-31 |
| NCT07791758 A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma Single-country: China (10 sites) Decision brief → | Ph1/Ph2 | Nanjing Leads Biolabs Co.,Ltd | recruiting | 2026-08-28 | 2030-09-04 |
| NCT07790510 HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Haisco Pharmaceutical Group Co., Ltd. | recruiting | 2026-08-27 | 2029-09-30 |
| NEORAF · NCT07789210 A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases Single-country: China (1 site) Decision brief → | Ph2 | Zhejiang University | recruiting | 2026-08-27 | 2029-12-31 |
| NCT07779694 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer No sites listed Decision brief → | Ph2 | Zhejiang University | not yet recruiting | 2026-08-21 | 2028-12-31 |
| SSIBLING · NCT07775209 Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma Single-country: United States (1 site) Decision brief → | Ph2 | University of Vermont Medical Center | enrolling by invitation | 2026-08-20 | 2039-05 |
| RADIANT · NCT07774754 Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial Single-country: China (1 site) Decision brief → | Ph2 | Sun Yat-sen University | not yet recruiting | 2026-08-19 | 2028-01-01 |
| CRI-KEV · NCT07765667 NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Single-country: China (1 site) Decision brief → | Ph2 | Sixth Affiliated Hospital, Sun Yat-sen University | not yet recruiting | 2026-08-14 | 2029-09-01 |
| HAIP-6192 · NCT07764497 Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis Single-country: Canada (1 site) Decision brief → | Ph2 | Sunnybrook Health Sciences Centre | recruiting | 2026-08-14 | 2036-12 |
| NCT07755124 Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial No sites listed Decision brief → | Ph1/Ph2 | West China Hospital | not yet recruiting | 2026-08-10 | 2028-08 |
| NCT07752875 A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation No sites listed Decision brief → | Ph1/Ph2 | LG Chem | not yet recruiting | 2026-08-07 | 2032-10-31 |
| NCT07749586 A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Single-country: United States (4 sites) Decision brief → | Ph1/Ph2 | Arvinas Inc. | recruiting | 2026-08-06 | 2031-03-31 |
| NCT07750041 A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph1/Ph2 | CSPC Megalith Biopharmaceutical Co.,Ltd. | not yet recruiting | 2026-08-06 | 2027-12-31 |
| NCT07743723 A Study of IOV-5001 in Adults With Advanced Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Iovance Biotherapeutics, Inc. | not yet recruiting | 2026-08-04 | 2034-03 |
| RECTIFY-1 · NCT07735624 RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer Single-country: United States (3 sites) Decision brief → | Ph2 | Dana-Farber Cancer Institute | recruiting | 2026-07-30 | 2027-06-01 |
| NCT07737600 A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Lepu Biopharma Co., Ltd. | not yet recruiting | 2026-07-30 | 2028-12 |
| NCT07728019 Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM Single-country: China (1 site) Decision brief → | Ph2 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | recruiting | 2026-07-27 | 2029-06-30 |
| NCT07724223 Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC Single-country: China (1 site) Decision brief → | Ph2 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | recruiting | 2026-07-24 | 2028-10-01 |
| BOND-4 · NCT07722754 Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial Single-country: China (1 site) Decision brief → | Ph2 | Guangdong Provincial People's Hospital | recruiting | 2026-07-23 | 2028-07-31 |
| NCT07720115 Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer No sites listed Decision brief → | Ph2 | M.D. Anderson Cancer Center | withdrawn | 2026-07-22 | 2026-09-04 |
| NCT07718490 Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer Single-country: China (2 sites) Decision brief → | Ph2 | The First Affiliated Hospital with Nanjing Medical University | recruiting | 2026-07-22 | 2027-12-31 |
| NCT07714447 Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer Single-country: China (1 site) Decision brief → | Ph2 | Sun Yat-sen University | not yet recruiting | 2026-07-20 | 2029-02-01 |
| NCT07702292 [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications 2 countries, 0% of sites in the US Decision brief → | Ph2 | Blue Earth Diagnostics | recruiting | 2026-07-14 | 2028-02 |
| NCT07691489 A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | not yet recruiting | 2026-07-09 | 2029-06 |
| NCT07693751 A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer 2 countries, 67% of sites in the US Decision brief → | Ph1/Ph2 | SOTIO Biotech a.s. | recruiting | 2026-07-09 | 2027-11-29 |
| NCT07670312 Evaluation of XYA02 in Patients With Advanced Solid Tumors Single-country: Australia (5 sites) Decision brief → | Ph1/Ph2 | XYone Therapeutics, Inc | recruiting | 2026-06-26 | 2029-09-15 |
| NCT07668284 COQ10 and Vitamin E for Off-Target Radiation Toxicity Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Nebraska | not yet recruiting | 2026-06-25 | 2030-02-15 |
| NCT07662031 Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Single-country: United States (1 site) Decision brief → | Ph2 | Washington University School of Medicine | not yet recruiting | 2026-06-23 | 2030-12-31 |
| TARGET-D 203 · NCT07659795 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer 2 countries, 77% of sites in the US Decision brief → | Ph2 | Verastem, Inc. | recruiting | 2026-06-22 | 2027-06 |
| NCT07653685 A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer. Single-country: China (31 sites) Decision brief → | Ph1/Ph2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | recruiting | 2026-06-17 | 2027-06 |